Kraig Biocraft Laboratories Announces Successful Completion of Latest Recombinant Spider Silk Production Batch
Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully completed its fourth production cycle for 2024, achieving record-setting performance in parental silkworm lines and hybrid cocoons. The latest batch set new records for cocoon size, shell weight, and other key metrics for large-scale production of their BAM-1 spider silk line. The company reports improvements in both hybrid cocoons and parental silkworm lines, demonstrating comprehensive advancements throughout the production process. These achievements strengthen their position in sustainable, high-performance fiber production and indicate readiness for scaling to multi-ton production levels.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha completato con successo il suo quarto ciclo di produzione per il 2024, raggiungendo prestazioni da record nelle linee di bachi da seta parentali e nei bozzoli ibridi. L'ultimo lotto ha stabilito nuovi record per la dimensione dei bozzoli, il peso del guscio e altri parametri chiave per la produzione su larga scala della loro linea di seta di ragno BAM-1. L'azienda riporta miglioramenti sia nei bozzoli ibridi che nelle linee di bachi da seta parentali, dimostrando avanzamenti complessivi durante l'intero processo di produzione. Questi risultati rafforzano la loro posizione nella produzione di fibre sostenibili ad alte prestazioni e indicano la prontezza per una scalabilità ai livelli di produzione multi-tonnellata.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha completado con éxito su cuarto ciclo de producción para 2024, logrando un rendimiento récord en líneas de gusanos de seda parentales y en capullos híbridos. El último lote estableció nuevos récords en el tamaño de los capullos, el peso de la cáscara y otros indicadores clave para la producción a gran escala de su línea de seda de araña BAM-1. La empresa informa mejoras tanto en los capullos híbridos como en las líneas de gusanos de seda parentales, demostrando avances integrales durante todo el proceso de producción. Estos logros fortalecen su posición en la producción de fibras sostenibles y de alto rendimiento, e indican su preparación para escalar a niveles de producción de múltiples toneladas.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 2024년 네 번째 생산 주기를 성공적으로 완료하며 부모 실크 애벌레 라인과 하이브리드 고치에서 기록적인 성과를 달성했습니다. 최신 배치는 BAM-1 거미 실크 라인의 대규모 생산을 위한 고치 크기, 껍질 무게 및 기타 주요 지표에서 새로운 기록을 세웠습니다. 회사는 하이브리드 고치와 부모 실크 애벌레 라인 모두에서 개선을 보고하며, 생산 과정 전반에 걸쳐 포괄적인 발전을 입증하고 있습니다. 이러한 성과는 지속 가능한 고성능 섬유 생산에서의 위치를 강화하며 다톤 폐쇄 단계로의 확장 준비가 되어 있음을 나타냅니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a réussi à compléter son quatrième cycle de production pour 2024, atteignant des performances record dans les lignées parentales de vers à soie et les cocons hybrides. Le dernier lot a établi de nouveaux records en matière de taille de cocon, de poids de coque et d'autres indicateurs clés pour la production à grande échelle de leur ligne de soie d'araignée BAM-1. L'entreprise rapporte des améliorations tant dans les cocons hybrides que dans les lignées parentales de vers à soie, en démontrant des avancées complètes tout au long du processus de production. Ces réalisations renforcent leur position dans la production de fibres durables et performantes et indiquent leur préparation à une montée en échelle vers des niveaux de production de plusieurs tonnes.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat erfolgreich seinen vierten Produktionszyklus für 2024 abgeschlossen und dabei Rekordleistungen in den elterlichen Seidenspinnerlinien und hybriden Kokons erzielt. Die letzte Charge stellte neue Rekorde in Bezug auf Kokongröße, Schalengewicht und andere Schlüsselmesswerte für die großflächige Produktion ihrer BAM-1 Spinnenseidenlinie auf. Das Unternehmen berichtet über Verbesserungen sowohl bei hybriden Kokons als auch bei elterlichen Seidenspinnerlinien, was umfassende Fortschritte im gesamten Produktionsprozess verdeutlicht. Diese Erfolge stärken ihre Position in der nachhaltigen und leistungsstarken Faserproduktion und zeigen die Bereitschaft zur Skalierung auf Mehrtonproduktionsniveaus.
- Record-setting production batch size for parental line cocoons
- New records in cocoon size and shell weight metrics
- Improvements in BAM-1 genetics and production capabilities
- Demonstrated ability to scale up to multi-ton production levels
- None.
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of advanced spider silk-based fibers, is pleased to announce the successful completion of its fourth production cycle for 2024. This achievement marks a significant milestone, with record-setting performance across nearly every tracked metric for parental silkworm lines and hybrid cocoons.
The latest production cycle delivered the largest single batch of parental line cocoons the Company has ever produced. On top of the record-setting size of this batch, Kraig Labs continues to see strong vitality and robustness.
Beyond the sheer size of this production batch, quantitative analysis of this batch demonstrated that the genetics of the BAM-1 continue to improve. This batch set new records for cocoon size, shell weight, and several other key metrics for large-scale production. These records were set not only our hybrid cocoons, but also for the parental silkworm lines, reflecting comprehensive improvements throughout the entire production process.
"The results of our fourth production cycle are outstanding, showcasing the performance and capability of our BAM-1 line," said founder and CEO of Kraig Labs, Kim Thompson. "Our ongoing advancements in genetic engineering and silkworm rearing techniques are paying off, and these achievements underscore our ability to reliably scale up production to meet growing market demands."
By achieving new records in both parental and hybrid silkworm metrics, the Company solidifies its leadership in the field of sustainable, high-performance fibers.
"The continuous improvement in nearly every tracked performance metric is a testament to the dedication and expertise of our team and the genetics of BAM-1," said the Company’s COO, Jon Rice. "Our comprehensive focus on genetic robustness and cocoon yield has paid off. We are well on track for scaling our operations to multi-ton levels while maintaining the quality and performance of our spider silk materials."
Kraig Biocraft Laboratories continues to pursue new heights in advanced biomaterials, driving innovation and setting new standards in the production of spider silk fibers.
The Company will hold an investor conference call later this month at a time to be announced in the coming weeks.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What records did Kraig Biocraft (KBLB) break in their fourth production cycle of 2024?
How successful was Kraig Biocraft's (KBLB) BAM-1 spider silk line performance in 2024?
What production scale is Kraig Biocraft (KBLB) targeting with their spider silk technology?
